This is a drug that acts as an inhibitor of the dopamine transporter protein. This protein is responsible for clearing dopamine and norepinephrine from the synaptic cleft in presynaptic neurons. Therefore, inhibiting it leads to increased concentrations of dopamine and norepinephrine in the synaptic cleft. Thus, 2FDCK would be expected to have stimulant effects similar to those of amphetamines: however, it also has been shown to possess antipsychotic properties in primate models of psychos through its enhancement of dopamine and norepinephrine signaling